Aurinia Pharmaceuticals (AUPH)
Market Price (2/24/2026): $14.97 | Market Cap: $2.0 BilSector: Health Care | Industry: Biotechnology
Aurinia Pharmaceuticals (AUPH)
Market Price (2/24/2026): $14.97Market Cap: $2.0 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -14% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 23x |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 33% | Key risksAUPH key risks include [1] its heavy reliance on a single product, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 45%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 45% | |
| Attractive yieldFCF Yield is 6.1% | |
| Low stock price volatilityVol 12M is 45% | |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -14% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 33% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 45%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 45% |
| Attractive yieldFCF Yield is 6.1% |
| Low stock price volatilityVol 12M is 45% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 23x |
| Key risksAUPH key risks include [1] its heavy reliance on a single product, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Aurinia Pharmaceuticals (AUPH) stock has gained about 15% since 10/31/2025 because of the following key factors:
1. Strong Q3 2025 Financial Performance and Upgraded Full-Year Guidance
Aurinia Pharmaceuticals reported robust financial results for the third quarter of 2025, significantly boosting investor confidence. Total revenue for the three and nine months ended September 30, 2025, increased by 8% and 17% respectively, compared to the same periods in 2024. Net product sales of LUPKYNIS, the company's FDA-approved therapy for lupus nephritis, saw even more substantial growth, rising by 27% and 24% for the respective periods. The company also raised its full-year 2025 total revenue guidance from a range of $260-270 million to $275-280 million, and net product sales guidance from $250-260 million to $265-270 million, indicating a positive outlook for future earnings. Furthermore, net income and diluted earnings per share experienced considerable increases.
2. Positive Analyst Sentiment and Price Target Increases
Following the strong financial results, Aurinia Pharmaceuticals received positive attention from Wall Street analysts, leading to upward revisions in price targets and a generally bullish outlook. On November 17, 2025, the average one-year price target for AUPH was increased by 34.15% to $16.03 per share from a prior estimate. Jefferies notably upgraded Aurinia Pharmaceuticals on November 7, 2025, with a price target of $21.00. As of early February 2026, the consensus analyst rating for AUPH was a "Strong Buy," with a median price target of $16.50, suggesting a potential upside from its trading price.
Show more
1. Strong Q3 2025 Financial Performance and Upgraded Full-Year Guidance
Aurinia Pharmaceuticals reported robust financial results for the third quarter of 2025, significantly boosting investor confidence. Total revenue for the three and nine months ended September 30, 2025, increased by 8% and 17% respectively, compared to the same periods in 2024. Net product sales of LUPKYNIS, the company's FDA-approved therapy for lupus nephritis, saw even more substantial growth, rising by 27% and 24% for the respective periods. The company also raised its full-year 2025 total revenue guidance from a range of $260-270 million to $275-280 million, and net product sales guidance from $250-260 million to $265-270 million, indicating a positive outlook for future earnings. Furthermore, net income and diluted earnings per share experienced considerable increases.
2. Positive Analyst Sentiment and Price Target Increases
Following the strong financial results, Aurinia Pharmaceuticals received positive attention from Wall Street analysts, leading to upward revisions in price targets and a generally bullish outlook. On November 17, 2025, the average one-year price target for AUPH was increased by 34.15% to $16.03 per share from a prior estimate. Jefferies notably upgraded Aurinia Pharmaceuticals on November 7, 2025, with a price target of $21.00. As of early February 2026, the consensus analyst rating for AUPH was a "Strong Buy," with a median price target of $16.50, suggesting a potential upside from its trading price.
Show more
Stock Movement Drivers
Fundamental Drivers
The 12.6% change in AUPH stock from 10/31/2025 to 2/23/2026 was primarily driven by a 25.6% change in the company's Net Income Margin (%).| (LTM values as of) | 10312025 | 2232026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.17 | 14.83 | 12.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 260 | 266 | 2.2% |
| Net Income Margin (%) | 23.3% | 29.3% | 25.6% |
| P/E Multiple | 29.3 | 25.1 | -14.3% |
| Shares Outstanding (Mil) | 135 | 132 | 2.3% |
| Cumulative Contribution | 12.6% |
Market Drivers
10/31/2025 to 2/23/2026| Return | Correlation | |
|---|---|---|
| AUPH | 12.6% | |
| Market (SPY) | 0.0% | 13.8% |
| Sector (XLV) | 9.9% | 27.7% |
Fundamental Drivers
The 60.4% change in AUPH stock from 7/31/2025 to 2/23/2026 was primarily driven by a 25.6% change in the company's Net Income Margin (%).| (LTM values as of) | 7312025 | 2232026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.24 | 14.83 | 60.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 260 | 266 | 2.2% |
| Net Income Margin (%) | 23.3% | 29.3% | 25.6% |
| P/E Multiple | 20.6 | 25.1 | 22.1% |
| Shares Outstanding (Mil) | 135 | 132 | 2.3% |
| Cumulative Contribution | 60.4% |
Market Drivers
7/31/2025 to 2/23/2026| Return | Correlation | |
|---|---|---|
| AUPH | 60.4% | |
| Market (SPY) | 8.3% | 12.5% |
| Sector (XLV) | 22.1% | 27.3% |
Fundamental Drivers
The 86.5% change in AUPH stock from 1/31/2025 to 2/23/2026 was primarily driven by a 42.5% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2232026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.95 | 14.83 | 86.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 220 | 266 | 20.6% |
| P/S Multiple | 5.2 | 7.4 | 42.5% |
| Shares Outstanding (Mil) | 143 | 132 | 8.5% |
| Cumulative Contribution | 86.5% |
Market Drivers
1/31/2025 to 2/23/2026| Return | Correlation | |
|---|---|---|
| AUPH | 86.5% | |
| Market (SPY) | 14.4% | 28.4% |
| Sector (XLV) | 9.4% | 30.5% |
Fundamental Drivers
The 63.9% change in AUPH stock from 1/31/2023 to 2/23/2026 was primarily driven by a 106.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312023 | 2232026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.05 | 14.83 | 63.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 129 | 266 | 106.1% |
| P/S Multiple | 10.0 | 7.4 | -26.1% |
| Shares Outstanding (Mil) | 142 | 132 | 7.6% |
| Cumulative Contribution | 63.9% |
Market Drivers
1/31/2023 to 2/23/2026| Return | Correlation | |
|---|---|---|
| AUPH | 63.9% | |
| Market (SPY) | 74.1% | 26.1% |
| Sector (XLV) | 24.4% | 24.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AUPH Return | 65% | -81% | 108% | -0% | 78% | -10% | 4% |
| Peers Return | 29% | 12% | -16% | 9% | 24% | 12% | 85% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 84% |
Monthly Win Rates [3] | |||||||
| AUPH Win Rate | 67% | 33% | 67% | 67% | 58% | 0% | |
| Peers Win Rate | 62% | 55% | 37% | 55% | 63% | 90% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| AUPH Max Drawdown | -28% | -82% | 0% | -46% | -20% | -11% | |
| Peers Max Drawdown | -5% | -11% | -24% | -12% | -9% | -2% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BMY, GILD, ABBV, JNJ, PFE.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/23/2026 (YTD)
How Low Can It Go
| Event | AUPH | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -87.6% | -25.4% |
| % Gain to Breakeven | 704.9% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -47.2% | -33.9% |
| % Gain to Breakeven | 89.2% | 51.3% |
| Time to Breakeven | 545 days | 148 days |
| 2018 Correction | ||
| % Loss | -63.2% | -19.8% |
| % Gain to Breakeven | 171.6% | 24.7% |
| Time to Breakeven | 52 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -90.1% | -56.8% |
| % Gain to Breakeven | 911.6% | 131.3% |
| Time to Breakeven | 1,814 days | 1,480 days |
Compare to BMY, GILD, ABBV, JNJ, PFE
In The Past
Aurinia Pharmaceuticals's stock fell -87.6% during the 2022 Inflation Shock from a high on 10/29/2021. A -87.6% loss requires a 704.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Aurinia Pharmaceuticals (AUPH)
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
AI Analysis | Feedback
Here are a few brief analogies for Aurinia Pharmaceuticals (AUPH):
- Like an early-stage Vertex Pharmaceuticals, but exclusively focused on lupus nephritis instead of cystic fibrosis.
- A specialized biotech, similar to a focused Amgen, with its primary commercial product targeting lupus nephritis.
AI Analysis | Feedback
- LUPKYNIS (voclosporin): An oral prescription medication used for the treatment of adult patients with active lupus nephritis.
AI Analysis | Feedback
Aurinia Pharmaceuticals (AUPH) sells primarily to other companies rather than directly to individuals. As a pharmaceutical company, its primary customers are major wholesale pharmaceutical distributors who then distribute LUPKYNIS (voclosporin) to pharmacies, hospitals, and other healthcare providers.
Based on their SEC filings, the major customer companies that accounted for substantially all of Aurinia Pharmaceuticals' revenue are:
- AmerisourceBergen Drug Corporation (NYSE: ABC)
- McKesson Corporation (NYSE: MCK)
- Cardinal Health, Inc. (NYSE: CAH)
AI Analysis | Feedback
- Recipharm OT Chemistry AB (RECI B)
- Siegfried AG (SFZN)
- Thermo Fisher Scientific Inc. (TMO)
- Catalent Pharma Solutions LLC (CTLT)
AI Analysis | Feedback
Peter Greenleaf, President, Chief Executive Officer and Director
Mr. Greenleaf has served as President, Chief Executive Officer, and Director of Aurinia since 2019. He previously served as CEO and Director of Cerecor Inc. from 2018 to 2019. From 2014 to 2018, he was CEO and Chairman of Sucampo Pharmaceuticals, Inc., which was acquired by Mallinckrodt plc for $1.2 billion. He also held roles as Chairman of BioDelivery Sciences International, Inc. and Director of Antares Pharma, Inc., both of which were acquired by other pharmaceutical companies. Earlier in his career, he was CEO and Director of Histogenics Corporation (2013-2014) and served as President of MedImmune, Inc. (now AstraZeneca PLC), and President of MedImmune Ventures, Inc., a venture capital fund within AstraZeneca Group. Mr. Greenleaf currently serves as an Advisory for Petrichor Healthcare Capital Management LP, a private equity firm, and as Chairman of Revolo Biotherapeutics Ltd. and Maryland Venture Fund.
Joe Miller, Chief Financial Officer
Mr. Miller has served as Chief Financial Officer of Aurinia since 2020. Prior to joining Aurinia, he served as Chief Financial Officer, Principal Executive Officer, and Corporate Secretary at Cerecor Inc. from 2018 to 2020, where he oversaw acquisitions and led the divestiture of the company's commercial portfolio. From 2015 to 2018, he was Vice President of Finance at Sucampo Pharmaceuticals, Inc., which was acquired by Mallinckrodt plc for $1.2 billion in 2018. His earlier experience includes various finance and management positions at QIAGEN N.V., Eppendorf, Inc., and KPMG LLP.
Max Donley, Chief Operating Officer
Mr. Donley has served as Chief Operating Officer of Aurinia since 2024, and previously as Executive Vice President, Operations and Strategy from 2019 to 2024. Before Aurinia, he was Global Head of Human Resources, Information Technology, and Facilities at Senseonics Holdings, Inc. From 2014 to 2018, he was Executive Vice President of Global Human Resources, Information Technology, and Corporate Strategy at Sucampo Pharmaceuticals, Inc., through its acquisition by Mallinckrodt plc. He also served as Executive Vice President, Human Resources and Corporate Affairs at MedImmune, Inc. (now AstraZeneca PLC) from 2000 to 2013.
Dr. Volker Knappertz, Executive Vice President of Research & Development
Dr. Knappertz joined Aurinia in July 2022 as Executive Vice President of Research & Development. Prior to Aurinia, he was Executive Vice President of Research & Development and Chief Medical Officer at GW Pharmaceuticals, where he played a key role in the transformation of the company and securing FDA approval for Epidiolex. GW Pharmaceuticals was later acquired by Jazz Pharmaceuticals. He also held leadership positions at Teva Pharmaceuticals, AstraZeneca, and Bayer, contributing to several drug approvals and business development deals. Dr. Knappertz is a US board-certified neurologist.
Stephen Robertson, Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer
Mr. Robertson has served as Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer since 2020. Before joining Aurinia, he was a Partner at Borden Ladner Gervais LLP from 2014 to 2020. He also served as an Adjunct Professor at the Allard School of Law at the University of British Columbia from 2015 to 2020.
AI Analysis | Feedback
Key Risks to Aurinia Pharmaceuticals (AUPH)
- Heavy Reliance on a Single Product: Aurinia Pharmaceuticals is heavily dependent on its sole approved product, Lupkynis (voclosporin), for nearly all of its revenue. Any adverse developments related to Lupkynis, such as regulatory issues, reimbursement challenges, or safety concerns, could severely impact the company's financial performance and overall business stability.
- Increasing Competition for Lupkynis: The market for lupus nephritis treatments is becoming increasingly competitive. The recent approval of Roche's Gazyva in October 2025 presents a significant threat, as it is a newly approved competitor that could capture market share from Lupkynis. Additionally, other emerging therapies, including CAR-T treatments and biologics, are in development and could further erode Lupkynis's market position.
- Patent Litigation and Potential Loss of Exclusivity for Lupkynis: Aurinia is facing ongoing patent challenges from generic drug manufacturers, including Sandoz, Dr. Reddy's, and Teva, which initiated Paragraph IV ANDA notices in May 2025. The outcomes of these lawsuits are uncertain, and an unfavorable decision could lead to an earlier-than-expected loss of market exclusivity for Lupkynis, significantly impacting future revenue streams. While a dosing protocol patent extends to 2037, the composition of matter patent is listed to expire in October 2025, and both have faced challenges.
AI Analysis | Feedback
The potential approval and market entry of novel therapies for lupus nephritis currently in late-stage development, such as Novartis's ianalumab (BAFF receptor antagonist) which is in Phase 3 trials.
AI Analysis | Feedback
Aurinia Pharmaceuticals' primary product is LUPKYNIS (voclosporin), an FDA-approved oral therapy designed for adult patients with active lupus nephritis (LN). The addressable markets for lupus nephritis are substantial and are projected to grow across various regions:- The global lupus nephritis market was valued at approximately USD 1.24 billion in 2023 and is projected to reach USD 2.17 billion by 2032, demonstrating a Compound Annual Growth Rate (CAGR) of 6.3%. Other estimates place the global market value at USD 2.02 billion in 2023, with a projected growth to around USD 3.21 billion by 2030 at a CAGR of 6.8%. Another source indicates a global market value of USD 2.21 billion in 2025, expected to reach USD 6.28 billion by 2035 with a CAGR of 11%.
- In the top 7 markets (U.S., EU4 - Germany, Spain, Italy, and France, UK, and Japan), the lupus nephritis market reached a value of USD 2.4 billion in 2024. This market is expected to grow to USD 6.0 billion by 2035, exhibiting a CAGR of 8.7% during 2025-2035.
- The United States represents a significant portion of this market, accounting for approximately 85% of the total market size in the 7MM (United States, EU4, UK, and Japan) in 2024. The lupus nephritis treatment industry in the United States is predicted to grow at a CAGR of 12.5% during 2025 to 2035.
AI Analysis | Feedback
Aurinia Pharmaceuticals (AUPH) is anticipated to experience future revenue growth driven by several key factors over the next 2-3 years:
- Continued Growth of LUPKYNIS in Lupus Nephritis: LUPKYNIS (voclosporin) is expected to maintain strong sales momentum for the treatment of lupus nephritis. The company has repeatedly raised its 2025 revenue guidance, citing the continued strong demand and the drug's inclusion in the American College of Rheumatology (ACR) lupus nephritis treatment guidelines, which recommend its incorporation into first-line therapy. This guideline update encourages earlier and more aggressive treatment with therapies like LUPKYNIS to preserve kidney function.
- Increased Patient Persistency for LUPKYNIS: The persistency rate of patients on LUPKYNIS therapy has shown an upward trend, indicating that patients are remaining on the treatment for longer durations. This improved adherence contributes to more sustained and predictable revenue streams for the company.
- International Expansion of LUPKYNIS: Aurinia's partnership with Otsuka Pharmaceutical Co. for the commercialization of LUPKYNIS in various territories, including Japan, is a driver of revenue growth. Milestone payments associated with regulatory approvals in these regions, such as the one for Japan in 2024, contribute to total revenue, and continued sales by Otsuka in their commercialized territories are expected.
- Advancement of Aritinercept (AUR200) into Clinical Studies for New Autoimmune Indications: Aurinia is actively progressing its pipeline, with plans to initiate clinical studies for aritinercept, a dual inhibitor of BAFF and APRIL, in two autoimmune diseases by the end of 2025. The company anticipates disclosing further details about its development plan for this new asset in early 2026, which could open new revenue streams if successful.
- Strategic Price Adjustments for LUPKYNIS: While not a primary driver, the company has implemented small, incremental price increases for LUPKYNIS over time, which contribute to the overall net revenue per patient.
AI Analysis | Feedback
Aurinia Pharmaceuticals (AUPH) has made the following significant capital allocation decisions over the last 3-5 years:Share Repurchases
- In the first six months of 2025, Aurinia repurchased 11.2 million shares for $90.8 million.
- Since the buyback program began in February 2024, the company has repurchased a total of 18.3 million shares for $138.4 million as of July 2025.
- As of September 30, 2025, Aurinia repurchased 12.2 million common shares for $98.2 million during the first nine months of 2025.
Share Issuance
- Proceeds from the issuance of common shares under the Employee Stock Purchase Plan (ESPP) were $401,000 for the nine months ended September 30, 2025.
- For the nine months ended September 30, 2025, the company reported $2,062,000 from the issuance of common shares from the exercise of stock options and vesting of RSUs.
Capital Expenditures
- Aurinia completed a capital expenditure program for the Monoplant totaling $23.7 million, with an $11.8 million payment in February 2021 and an $11.9 million payment in late June 2023.
- Capital expenditures were $0.40 million in the first six months of 2025, $0.28 million in 2024, $0.72 million in 2023, $0.29 million in 2022, $1.50 million in 2021, and $7.34 million in 2020.
Latest Trefis Analyses
Trade Ideas
Select ideas related to AUPH.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | ABT | Abbott Laboratories | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 5.5% | 5.5% | -1.0% |
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -15.6% | -15.6% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 19.4% | 19.4% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 15.3% | 15.3% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -42.4% | -42.4% | -42.4% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 105.54 |
| Mkt Cap | 170.0 |
| Rev LTM | 53,920 |
| Op Inc LTM | 14,044 |
| FCF LTM | 11,610 |
| FCF 3Y Avg | 11,036 |
| CFO LTM | 13,616 |
| CFO 3Y Avg | 13,265 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.0% |
| Rev Chg 3Y Avg | 1.9% |
| Rev Chg Q | 5.7% |
| QoQ Delta Rev Chg LTM | 1.5% |
| Op Mgn LTM | 27.8% |
| Op Mgn 3Y Avg | 22.6% |
| QoQ Delta Op Mgn LTM | 1.2% |
| CFO/Rev LTM | 31.3% |
| CFO/Rev 3Y Avg | 28.6% |
| FCF/Rev LTM | 29.1% |
| FCF/Rev 3Y Avg | 24.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 170.0 |
| P/S | 6.3 |
| P/EBIT | 17.3 |
| P/E | 22.5 |
| P/CFO | 17.8 |
| Total Yield | 6.6% |
| Dividend Yield | 2.5% |
| FCF Yield 3Y Avg | 6.1% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 7.9% |
| 3M Rtn | 13.9% |
| 6M Rtn | 27.6% |
| 12M Rtn | 28.7% |
| 3Y Rtn | 69.0% |
| 1M Excs Rtn | 9.5% |
| 3M Excs Rtn | 11.2% |
| 6M Excs Rtn | 18.9% |
| 12M Excs Rtn | 17.3% |
| 3Y Excs Rtn | 3.8% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA213716 | LUPKYNIS | voclosporin | capsule | 1222021 | -15.9% | -23.6% | 9.4% | -43.9% | -0.2% |
Price Behavior
Price Behavior
| Market Price | $14.83 | |
| Market Cap ($ Bil) | 2.0 | |
| First Trading Date | 02/21/2008 | |
| Distance from 52W High | -9.4% | |
| 50 Days | 200 Days | |
| DMA Price | $15.14 | $12.12 |
| DMA Trend | up | down |
| Distance from DMA | -2.1% | 22.3% |
| 3M | 1YR | |
| Volatility | 29.7% | 45.5% |
| Downside Capture | 65.23 | 68.74 |
| Upside Capture | 5.59 | 123.22 |
| Correlation (SPY) | 21.2% | 28.9% |
AUPH Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.15 | -0.02 | 0.27 | 0.84 | 0.67 | 0.87 |
| Up Beta | 2.21 | 0.95 | 1.22 | 2.07 | 0.70 | 0.73 |
| Down Beta | -0.40 | -0.40 | -0.39 | 0.23 | 0.29 | 0.55 |
| Up Capture | -137% | -55% | 61% | 109% | 131% | 129% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 7 | 17 | 30 | 60 | 125 | 359 |
| Down Capture | 51% | 64% | 6% | 35% | 75% | 103% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 12 | 23 | 29 | 61 | 120 | 377 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AUPH | |
|---|---|---|---|---|
| AUPH | 90.4% | 45.4% | 1.56 | - |
| Sector ETF (XLV) | 9.2% | 17.3% | 0.35 | 30.6% |
| Equity (SPY) | 12.8% | 19.4% | 0.50 | 28.4% |
| Gold (GLD) | 79.1% | 25.7% | 2.25 | -2.7% |
| Commodities (DBC) | 7.7% | 16.9% | 0.27 | -4.0% |
| Real Estate (VNQ) | 6.6% | 16.7% | 0.21 | 26.2% |
| Bitcoin (BTCUSD) | -30.9% | 44.9% | -0.69 | 10.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AUPH | |
|---|---|---|---|---|
| AUPH | -1.0% | 68.7% | 0.28 | - |
| Sector ETF (XLV) | 8.1% | 14.5% | 0.37 | 22.3% |
| Equity (SPY) | 13.2% | 17.0% | 0.61 | 27.0% |
| Gold (GLD) | 23.6% | 17.1% | 1.12 | 5.2% |
| Commodities (DBC) | 10.7% | 19.0% | 0.45 | -0.5% |
| Real Estate (VNQ) | 5.1% | 18.8% | 0.18 | 24.0% |
| Bitcoin (BTCUSD) | 6.7% | 57.1% | 0.34 | 13.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AUPH | |
|---|---|---|---|---|
| AUPH | 20.7% | 75.1% | 0.59 | - |
| Sector ETF (XLV) | 11.3% | 16.5% | 0.57 | 19.6% |
| Equity (SPY) | 15.7% | 17.9% | 0.75 | 21.8% |
| Gold (GLD) | 15.1% | 15.6% | 0.81 | 3.3% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | 5.0% |
| Real Estate (VNQ) | 6.9% | 20.7% | 0.30 | 15.7% |
| Bitcoin (BTCUSD) | 67.8% | 66.8% | 1.07 | 7.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/31/2025 | 2.2% | 28.3% | 33.5% |
| 11/7/2024 | 10.9% | 10.1% | 18.8% |
| 8/1/2024 | -4.6% | -9.5% | 17.3% |
| 2/15/2024 | -24.5% | -24.7% | -35.1% |
| 11/2/2023 | 10.5% | 13.0% | 27.1% |
| 8/3/2023 | 4.2% | -6.6% | -10.5% |
| 5/4/2023 | -3.0% | -3.8% | -18.4% |
| 8/5/2021 | 23.1% | 30.3% | 49.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 5 | 4 | 6 |
| # Negative | 4 | 5 | 3 |
| Median Positive | 10.5% | 20.7% | 22.9% |
| Median Negative | -11.2% | -9.5% | -18.4% |
| Max Positive | 23.1% | 30.3% | 49.8% |
| Max Negative | -24.5% | -24.7% | -35.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 07/31/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/15/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 02/28/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Tang, Kevin | LP | Buy | 8052025 | 10.12 | 1,000,000 | 10,120,000 | 111,618,540 | Form | |
| 2 | Tang, Kevin | LP | Buy | 8052025 | 11.34 | 100,000 | 1,134,000 | 126,208,530 | Form | |
| 3 | Tang, Kevin | LP | Buy | 8052025 | 11.68 | 200,000 | 2,336,000 | 132,328,560 | Form | |
| 4 | Keenan, Greg | Chief Medical Officer | Direct | Sell | 8052025 | 10.50 | 20,000 | 210,000 | 1,401,582 | Form |
| 5 | Keenan, Greg | Chief Medical Officer | Direct | Sell | 3072025 | 8.23 | 8,305 | 68,350 | 1,263,173 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.